TAE Life Sciences

TAE Life Sciences is an American developer of oncology treatment technologies, utilizing the principles of biological targeting and radiation technology. It primarily provides Boron Neutron Capture Therapy (BNCT) for malignant tumor patients, characterized by compactness, cost-effectiveness, high precision, and reliability. The therapy is applied in the treatment of head and neck cancers and brain cancer and used for precise treatment at the cellular level. TAE Life Sciences is currently developing a novel biotargeted radiotherapy based on Boron Neutron Capture Therapy (BNCT) to improve the lives of patients with rapidly spreading, infiltrative, and recurrent cancers that do not respond to other cancer therapies. TLS is the only company with a comprehensive portfolio of targeted drugs and neutron technology, capable of delivering next-generation combination cancer treatments as a first-line therapy for patients globally.